Indegene Fair Value
Indegene fair value. Indegene (INDGN) average fair value is ₹533.28 across 8 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹645.4 (-17.37%), fair value range ₹81.72–₹1840.89. Analyse INDGN promoter holding to track promoter, FII and institutional holdings.
Fair Value Analysis Export
INDGN Fair Value vs Current Price — Valuation Summary
INDGN average fair value, fair value range, price gap and valuation status across 8 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit INDGN share price.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Earnings Growth Model (PEG)
Peter Lynch Fair Value
Benjamin Graham Number
Discounted Cash Flow (DCF)
INDGN Fair Value Analysis — Data Sources & Coverage
Indegene financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
INDGN vs Healthcare Sector Peers — P/E, P/B & Market Cap
Indegene P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Pharmaids Pharmaceuticals | PHARMAID | -28.7 | 2.2 | ₹100 |
| Modern Diagnostic & Rese… | MDRC | - | 1.42 | ₹83 |
| Broach Lifecare Hospital | BROACH | 90.7 | 0.82 | ₹8 |
| Emcure Pharmaceuticals | EMCURE | 40.6 | 8.3 | ₹44,381 |
| Glen Industries | GLEN | 15.7 | 1.97 | ₹250 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.